Kevin Cooper, MD
- Chair, Department of Dermatology, UH Cleveland Medical Center
- Professor of Dermatology, CWRU School of Medicine
- Professor of Pathology, CWRU School of Medicine
- Henri Pell Junod, Jr. Chair in Dermatology, University Hospitals
- Specialty: Dermatology, Dermatology-Clinical and Lab Dermatological Immunology
-
Location:UH Cleveland Medical Center Bolwell
11100 Euclid Ave
Cleveland, OH 44106
- Call: 216-844-8200
Biography: Kevin Cooper, MD
Expertise
Certifications & Memberships
- Clinical and Laboratory Dermatological Immunology - American Board of Dermatology
- Dermatology - American Board of Dermatology
Education
Fellowship | Clinical and Laboratory Dermatological Immunology
Clinical and Laboratory Dermatological Immunology - National Institutes Of Health (1982 - 1985)
Fellowship | Immunodermatology
Immunodermatology - Oregon Health And Science University Hospital (1981 - 1982)
Residency | Dermatology
Dermatology - Oregon Health And Science University Hospital (1978 - 1981)
Internship | Dermatology
Dermatology - Oregon Health And Science University Hospital (1977 - 1978)
Medical Education
University Of Florida College Of Medicine (1977)
Undergraduate
University Of Florida (1973)
About
Kevin D. Cooper, MD, is a dermatologist at University Hospitals and Chair of the Department of Dermatology at UH Cleveland Medical Center. He is also a staff physician for the Dermatology Service at the Cleveland VA Hospital. Dr. Cooper is the director of the Skin Diseases Research Center at Case Western Reserve University/University Hospitals, focusing on creating advances in skin diseases, and the Director of the Murdough Family Center for Psoriasis.
Dr. Cooper attended medical school at the University of Florida and did his residency and fellowship training in dermatology and immunodermatology at Oregon Health Sciences University. He joined Case Western Reserve University and UH Cleveland Medical Center in 1995 after prior positions at the University of Michigan and the National Institutes of Health.
As Chair of the Department of Dermatology, Dr. Cooper and his team developed a clinical practice with 10 highly integrated dermatology suites throughout the region, all designed with an emphasis on excellence, respect and value. In addition to patient care, the department incorporates a variety of academic programs, such as clinical teaching and a wide-ranging portfolio of research and clinical trial investigations. Dr. Cooper’s research interests are in inflammatory-mediated skin diseases, lymphoma, and photomedicine/photoimmunology, with continuous funding through federal awards since 1986, and over 300 published papers and chapters. He enjoys mentoring faculty, residents, fellows and students across each of these dimensions.
Dr. Cooper is a co-inventor of the first biologic to be FDA-approved for psoriasis, and co-founded Fluence Therapeutics, a start-up biomedical company created to develop a novel photodynamic therapy for psoriasis and lymphoma. He enjoys consulting in the early phases of product development for skin care and pharmaceuticals. Dr. Cooper has served as President of the Society for Investigative Dermatology, President of the Association of Professors of Dermatology, and Vice President of the American Academy of Dermatology. He is Treasurer of the International Eczema Council and a Councilor for the International Psoriasis Council.
Research & Publications
Research Links
PubMed
View Research
Research Interests
Immunodermatology, cutaneous lymphoma research, translational research
Featured Videos
Watch to find out more about this University Hospitals provider.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Kevin Cooper disclosed the following Outside Relationships with Industry:
- - Fluence therapeutics - Ownership